Anbio Biotechnology (NNNN)

NASD · Healthcare · Medical Instruments & Supplies · Germany

Anbio Biotechnology is a small cap company (market value between $300 million and $2 billion) in the Medical Instruments & Supplies industry.

Intrinsic value, DCF valuation, financial health and value investing analysis for the Anbio Biotechnology stock.

Our verdict on NNNN

Overvalued: intrinsic value $1.49 per share, market price $3.36, margin of safety -126.0% (as of 2026-10-30).

Discounting its cash flows at 9.0% (average of 3 methods) values the shares at $1.49; the price of $3.36 is 126% above that value, and 76% of that value comes from beyond year five.

Browse

• Stocks in Germany

Peers in Medical Instruments & Supplies

• Intuitive Surgical Inc (ISRG)
• Becton Dickinson & Co (BDX)
• Medline Inc (MDLN)
• Alcon Inc (ALC)
• Resmed Inc (RMD)
• West Pharmaceutical Services Inc (WST)
• Solventum Corp (SOLV)
• Baxter International Inc (BAX)

All 51 Medical Instruments & Supplies stocks

Cheaper than NNNN in Medical Instruments & Supplies

• Solventum Corp (SOLV): undervalued, 50% margin of safety
• Pro-Dex Inc (PDEX): slightly undervalued, 11% margin of safety
• Resmed Inc (RMD): slightly undervalued, 7% margin of safety
• Cooper Companies Inc (COO): fairly valued, 3% margin of safety
• Becton Dickinson & Co (BDX): slightly overvalued, -6% margin of safety
• Aptargroup Inc (ATR): slightly overvalued, -12% margin of safety

13 more in this industry show a wider margin of safety.

Is NNNN undervalued or overvalued?

NNNN is overvalued (as of the 2026-10-30 close). Discounting its cash flows at 9.0% (average of 3 methods) values the shares at $1.49; the price of $3.36 is 126% above that value, and 76% of that value comes from beyond year five.

What is the intrinsic value of NNNN?

$1.49 per share (as of the 2026-10-30 close), against a market price of $3.36. That is a margin of safety of -126.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.